SUNNYVALE, Calif., Aug 18, 2005 /PRNewswire-FirstCall via COMTEX/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that Richard A. Miller, M.D., president and chief executive officer, is giving a talk entitled, "The Development of Novel Drugs Based on Redox Properties," at the Fourth Sino-US Symposium on Medicine in the 21st Century (SUSM) at 9:30 a.m. on Sunday, August 21st at the Holiday Inn-Golden Gateway in San Francisco, CA.
The SUSM was designed to foster an exchange of medical advancement information between China and the US, and is being sponsored by the University of California at San Francisco, School of Medicine.
Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and atherosclerosis. The company's products are rationally designed, ring-shaped small molecules called texaphyrins that are designed to selectively target and disrupt the bioenergetic processes of diseased cells, such as cancer and atherosclerotic plaque. More information about the company, its technology, and products in development can be found on its website at www.pharmacyclics.com. Pharmacyclics(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.
SOURCE Pharmacyclics, Inc.
Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or Carolyn Bumgardner Wang of WeissComm Partners, +1-415-946-1065, for Pharmacyclics, Inc.
Copyright (C) 2005 PR Newswire. All rights reserved.
News Provided by COMTEX